Drug Trial Radar · NCT02096601
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Aug 11, 2014
Primary completion
Mar 15, 2015
Study completion Mar 15, 2015
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research
- First posted
- Mar 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant catechol-O-methyl transferase \[COMT\] inhibitor) in PD subjects with well-defined morning "OFF" and a good response to LD. Exploratory efficacy parameters were collected (early evidence of effectiveness as part of Phase 1).
Conditions
- Parkinson's Disease
Interventions
LD/CD SC solutionDrug
Levodopa/carbidopa SC solution
EntacaponeDrug
Entacapone 200 mg oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events frequencyTime frame: Up to 6 weeks
- LD, CD and 3-OMD PK analysis from sample taken on Days 3, 4 and 5 will be used to determine the Fluctuation Index, its CV, AUC, Cmin, Cmax, and tmax.Time frame: Days 1, 2, 3 and 4
- Tolerability: Number of patients who discontinued due to adverse eventsTime frame: Up to 6 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Tel Aviv Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.